Rain Oncology Inc
Change company Symbol lookup
Select an option...
RAIN Rain Oncology Inc
FIX Comfort Systems USA Inc
DY Dycom Industries Inc
EXPO Exponent Inc
RTX Raytheon Technologies Corp
SEVN Seven Hills Realty Trust
$NQEG35LMGBPN Nasdaq Egypt Real Estate Large Mid C
JNJ Johnson & Johnson
TATT TAT Technologies Ltd
MMM 3M Co
Go

Health Care : Pharmaceuticals |
Company profile

Rain Oncology Inc., formerly Rain Therapeutics Inc., is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.

Postmarket

Last Trade
Delayed
$9.67
-0.01 (-0.10%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$9.68
Day's Change
-0.34 (-3.39%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
10.46
Day's Low
9.50
Volume
(Heavy Day)
Volume:
354,337

10-day average volume:
286,563
354,337

Rain Therapeutics to Participate in H.C. Wainwright's 3rd Annual Precision Oncology Virtual Conference

8:00 am ET November 14, 2022 (Globe Newswire) Print
Rain Therapeutics to Participate in H.C. Wainwright's 3rd Annual Precision Oncology Virtual ConferenceGlobeNewswireNovember 14, 2022

NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), ("Rain") a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in H.C. Wainwright's 3rd Annual Precision Oncology Conference on November 14, 2022.

Company management will participate in one-on-one investor meetings, and Avanish Vellanki, CEO, will be participating in a fireside chat on Monday, November 14 at 1:00 PM ET. The webcast of the fireside chat is linked here.

If you would like to request a meeting with management, please contact your H.C. Wainwright representative.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. Rain's lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Investor Contact

Dan Ferry

LifeSci Advisors

+1.617.430.7576

daniel@lifesciadvisors.com

Media Contact

Jordyn Temperato

LifeSci Communications

jtemperato@lifescicomms.com



Primary Logo

comtex tracking

COMTEX_418842732/2010/2022-11-14T08:00:15

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.